Stephanie A Massaro MD

Clinical Interests

Pediatric cancer; leukemia, lymphoma and solid tumors, pediatric blood disorders; immune mediated thrombocytopenia, anemia and neutropenia, platelet disorders, bone marrow failure syndromes


Patient Care Locations

stephanie_massarofaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Chordoma, Desmoid Tumor, Adult Rhabdomyosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, and Soft TissueA COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol (COG 9902)
Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia, and Lymphoid LeukemiaTreatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (AALL0932) (CIRB)
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4S Neuroblastoma, and Brain and Nervous SystemANBL0032: PHASE III RANDOMIZED STUDY OF CHIMERIC ANTIBODY 14.18 (Ch14.18) IN HIGH RISK NEUROBLASTOMA FOLLOWING MYELOABLATIVE THERAPY AND AUTOLOGOUS STEM CELL RESCUE
Leukemia, not otherwise specifiedA Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND#73789, NSC#606869) in the Very Hish Risk Stratum (COG AALL1131)(CIRB)
Cancer and Myeloid and Monocytic LeukemiaAAML1031 A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC#681239, NSC#724772) for patients with High Allelic Ratio FLT3/ITD; A Groupwide II/III Study

More Clinical Trials...

Edit Profile